Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00798642 · ClinicalTrials.gov registry record · NA

Ulcerative Colitis Relapse Prevention Trial, Hypnosis

A NA study of Ulcerative Colitis and Inflammatory Bowel Disease, sponsored by Northwestern University.

Completed
Registry status
NA
Development phase
55
Enrollment target
1
Study location

NCT00798642: Completed NA study of Ulcerative Colitis and Inflammatory Bowel Disease, sponsored by Northwestern University.

NCT00798642 is a NA study of Ulcerative Colitis and Inflammatory Bowel Disease that has completed, run by Northwestern University. The registered enrollment target is 55 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00798642, a NA study of Ulcerative Colitis and Inflammatory Bowel Disease, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
NA
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

The UCRPT is a randomized controlled trial to determine if a type of hypnotherapy will maintain remission in patients affected by Ulcerative Colitis.

Interventions

  • BEHAVIORAL Hypnotherapy
  • BEHAVIORAL Standard care
  • BEHAVIORAL Mind Body Therapy

Study Locations (1)

Illinois

  • Northwestern University, Feinberg School of Medicine - Chicago

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2007-07
Est. Completion 2012-06
Phase NA
Northwestern University

1,209 total trials

What the finished NCT00798642 record still lists

NCT00798642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 3 interventions - of which Hypnotherapy is the first listed.

NCT00798642 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT00798642 about?

NCT00798642 is a clinical study titled "Ulcerative Colitis Relapse Prevention Trial, Hypnosis". The UCRPT is a randomized controlled trial to determine if a type of hypnotherapy will maintain remission in patients affected by Ulcerative Colitis.

What is the current status of trial NCT00798642?

This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2007-07. Estimated completion is 2012-06.

What conditions does trial NCT00798642 study?

This clinical trial studies the following conditions: Ulcerative Colitis, Inflammatory Bowel Disease.

What interventions are being tested in trial NCT00798642?

The interventions under investigation include: Hypnotherapy (BEHAVIORAL), Standard care (BEHAVIORAL), Mind Body Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT00798642?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00798642 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00798642's enrollment target sits among peer trials

55 83rd of 122 higher than 37 of 122 other Ulcerative Colitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00798642, the US trial registry maintained by the National Library of Medicine. NCT00798642 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.